Clinical trial Recruiting at 1 site Observational Ages 30 to 85

Registry for young and middle-aged patients with cerebral small vessel diseases and dementia risk

Official title: Dementia Risk Registry Across the Multidimensional Lifespan: A 10-Year Study(DREAM-10)

Run by Zhejiang Provincial People's Hospital · NCT06164262 · Data updated 2026-11-12

This study is trying to see how small blood vessel problems in the brain affect thinking skills in younger adults aged 30 to 60 who don’t have dementia yet.

More Health Behavior trials

Quick facts

Study typeObservational
Ages30 Years to 85 Years
SexAll
Enrollment1000 (estimated)
SponsorZhejiang Provincial People's Hospital
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedJanuary 1, 2024
Main results expectedAugust 1, 2034
Study endsDecember 1, 2034
Registry record updatedSeptember 17, 2026
Trial IDNCT06164262 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 30 to 60 years with MRI markers indicative of cerebral small vessel diseases and no known dementia.

Probably not a fit

Patients with known dementia or other cognitive diseases, as well as those with serious systemic illnesses, will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the relationship between cerebral small vessel diseases (CSVD) and cognitive impairment in individuals aged 30 to 60 years who show imaging markers of CSVD but do not have known dementia. Participants will undergo neuropsychological assessments and multimodal MRI scans, along with Optical Coherence Tomography Angiography (OCTA) to evaluate retinal health. The study will collect clinical data and follow participants over time to better understand the progression of cognitive decline in this demographic. By focusing on younger patients, the study seeks to fill a gap in knowledge regarding CSVD's impact on cognitive health.

Why it matters

Potential benefit: If successful, this study could lead to early identification and intervention strategies for dementia in younger individuals with CSVD.

How similar studies have gone: While studies on CSVD and dementia in older populations have shown significant findings, this specific focus on younger patients is relatively novel and less explored.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with any of the CSVD-related MRI imaging markers, including recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and superficial cortical siderosis.
2. Patients aged from 30 to 60 years.
3. Sign informed consent.

Exclusion Criteria:

1. Unable to cooperate with inspectors.
2. Known dementia.
3. Other cognitive diseases (such as Alzheimer's disease, Parkinson's disease, or thyroid disease).
4. Serious systemic illness, such as heart, liver, kidney disease or major mental illness.
5. Contraindications for imaging examination.

Exit Criteria:

1. Not meet the inclusion criteria.
2. For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator.
3. Any adverse or serious adverse events during the study period judged by investigator.

Where it's running

  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.